Date: 2017-12-26
Type of information: Nomination
Compound: presdient - chief executive officer
Company: Peregrine Pharmaceuticals (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 26, 2017, Peregrine Pharmaceuticals announced the appointment of Roger J. Lias as the company's new president and chief executive officer. Dr. Lias , who has more than 20 years of contract development and manufacturing organization (CDMO) management experience, currently sits on the Peregrine board of directors and serves as president of Avid Bioservices , Peregrine's wholly-owned CDMO subsidiary. Dr. Lias succeeds Steven W. King , who resigned as president and chief executive officer of Peregrine to pursue other professional interests.
- Dr. Lias' appointment is an important step in Peregrine's ongoing transition to a dedicated CDMO and builds upon the company's recent appointment of several proven CDMO industry veterans to the company's board and management team. Dr. Lias has previously held senior management positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma , Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias' achievements ranged from building start-up Cytovance's contract process development and biopharmaceutical cGMP production business, to increasing revenues at Diosynth from $16 million to $120 million over a four-year period.
- As part of this transformation, Peregrine is actively implementing a multi-pronged strategic plan designed to diversify and broaden its customer base and project mix, expand and strengthen its CDMO service offerings, and drive increased growth and profitability. Additionally, Peregrine is in the process of officially changing the company's name to Avid Bioservices and adopting a new NASDAQ ticker symbol. The company expects this process to be completed in early 2018.
Financial terms:
Latest news:
Is general: Yes
